SCHEMBL1061907

SCHEMBL1061907

C=CCOC12CC3CC(C1)CC(OCC=C)(C3)C2

nearest known ligand 0.34

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.34
ALDH1A1 P00352 1/20 0.34
KMT2A Q03164 1/20 0.34
EPHX2 P34913 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3840619 0.90 MEN1 (0.32) MEN1ALDH1A1KMT2A
SCHEMBL3849628 0.89
SCHEMBL3845442 0.88
SCHEMBL1056015 0.87 ALDH1A1 (0.30) ALDH1A1
SCHEMBL2343747 0.87 EPHX2 (0.36) MEN1ALDH1A1KMT2AEPHX2
SCHEMBL3845910 0.82 EPHX2 (0.30) EPHX2
SCHEMBL22494383 0.82 MEN1 (0.37) MEN1ALDH1A1KMT2A
SCHEMBL3845885 0.80
SCHEMBL4805947 0.78 MEN1 (0.30) MEN1ALDH1A1KMT2A
SCHEMBL3841069 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2216336-B1 PROCESS FOR PRODUCTION OF CYCLIC POLYORGANOSILOXANE, CURING AGENT, CURABLE COMPOSITION, AND CURED PRODUCT OF THE CURABLE COMPOSITION KANEKA CORP (JP) 2015-11-04 EP claimed
EP-1967540-B1 CURABLE COMPOSITION KANEKA CORP (JP) 2013-04-03 EP claimed
US-8273842-B2 Process for production of cyclic polyorganosiloxane, curing agent, curable composition, and cured product of the curable composition KANEKA CORPORATION (JP) 2012-09-25 US claimed
US-8263725-B2 Curable composition KANEKA CORPORATION (JP) 2012-09-11 US claimed
US-20100267919-A1 PROCESS FOR PRODUCTION OF CYCLIC POLYORGANOSILOXANE, CURING AGENT, CURABLE COMPOSITION, AND CURED PRODUCT OF THE CURABLE COMPOSITION KANEKA CORPORATION (JP) 2010-10-21 US claimed
US-20100222525-A1 CURABLE COMPOSITION KANEKA CORPORATION (JP) 2010-09-02 US claimed
EP-2216336-A1 PROCESS FOR PRODUCTION OF CYCLIC POLYORGANOSILOXANE, CURING AGENT, CURABLE COMPOSITION, AND CURED PRODUCT OF THE CURABLE COMPOSITION Kaneka Corporation (JP) 2010-08-11 EP claimed
EP-1967540-A1 CURABLE COMPOSITION Kaneka Corporation (JP) 2008-09-10 EP claimed
US-20260020362-A1 RIBBED SUBSTRATE AND OPTICAL SEMICONDUCTOR DEVICE KANEKA CORP (JP) 2026-01-15 US disclosed
US-20250066595-A1 CURABLE RESIN COMPOSITION THREEBOND CO., LTD. (JP) 2025-02-27 US disclosed
US-20250015105-A1 SUBSTRATE LAMINATE, IMAGE SENSOR, AND METHOD FOR MANUFACTURING SUSTRATE LAMINATE KANEKA CORPORATION (JP) 2025-01-09 US disclosed
EP-4455225-A1 CURABLE RESIN COMPOSITION ThreeBond Co., Ltd. (JP) 2024-10-30 EP disclosed
CN-118434809-A Curable resin composition 三键有限公司 2024-08-02 CN disclosed
US-20240206322-A1 OPTICAL SEMICONDUCTOR DEVICE, METHOD FOR MANUFACTURING SAME, SOLID-STATE IMAGING DEVICE, AND ELECTRONIC DEVICE KANEKA CORPORATION (JP) 2024-06-20 US disclosed
US-7754903-B2 adamantyl diglycidyl ether or 1-adamantanol epichlorohydrin adduct curable to polyepoxides; encapsulant for light-emitting diode; superior optical properties, heat resistance, photostability, and shrinkage inhibition TOKUYAMA CORPORATION (JP) 2010-07-13 US disclosed
JP-2008239579-A METHOD OF PRODUCING EPOXY COMPOUND TOKUYAMA CORP 2008-10-09 JP disclosed
EP-1967540-A1 CURABLE COMPOSITION Kaneka Corporation (JP) 2008-09-10 EP disclosed
JP-2007308397-A SILICON-CONTAINING ADAMANTANE COMPOUND TOKUYAMA CORP 2007-11-29 JP disclosed
US-20060252911-A1 adamantyl diglycidyl ether or 1-adamantanol epichlorohydrin adduct curable to polyepoxides; encapsulant for light-emitting diode; superior optical properties, heat resistance, photostability, and shrinkage inhibition TOKYUYAMA CORPORATION (JP) 2006-11-09 US disclosed
EP-1637526-A1 CURABLE POLYCYCLIC COMPOUNDS AND PROCESS FOR THE PRODUCTION THEREOF TOKUYAMA CORPORATION (JP) 2006-03-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260020362-A1 RIBBED SUBSTRATE AND OPTICAL SEMICONDUCTOR DEVICE SOST, CASK, STRADA MEN1 4264/4885ALDH1A1 477/4885KMT2A 4505/4885
US-20100267919-A1 PROCESS FOR PRODUCTION OF CYCLIC POLYORGANOSILOXANE, CURING AGENT, CURABLE COMPOSITION, AND CURED PRODUCT OF THE CURABLE COMPOSITION SMCHD1, SQLE, SMARCA5 MEN1 2819/4885ALDH1A1 1525/4885KMT2A 2334/4885
US-20060252911-A1 adamantyl diglycidyl ether or 1-adamantanol epichlorohydrin adduct curable to polyepoxides; encapsulant for light-emitting diode; superior optical properties, heat resistance, photostability, and shrinkage inhibition PFN1, FSCN1, PFDN1 MEN1 1965/4885ALDH1A1 50/4885KMT2A 1673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.